Related Experiment Video

Updated: Jun 16, 2025

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

3.7K

Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5

Qian Zhang1,2,3, Chunlin Zhang1,2, Changjiang Kang2,4

  • 1School of Life Sciences, Chongqing University, Chongqing, 401331, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|August 19, 2024
PubMed

Insights

Liraglutide accelerates diabetic wound healing by enhancing keratinocyte function via Myo1c and Dock5 interactions. These findings suggest liraglutide as a potential treatment for diabetic wound pathologies.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Wound Healing Research

Background:

  • Diabetic wounds present significant clinical challenges due to impaired cellular function.
  • Current treatments lack guideline-recommended hypoglycemic drugs for diabetic wound complications.
  • Understanding the molecular mechanisms of wound healing in diabetes is crucial.

Purpose of the Study:

  • To investigate the efficacy of liraglutide in accelerating diabetic wound closure.
  • To elucidate the underlying molecular mechanisms of liraglutide's action on keratinocytes.
  • To identify key protein interactions involved in liraglutide-mediated wound healing.

Main Methods:

  • Utilized diabetic mouse models (db/db and streptozotocin-induced).
  • Assessed wound closure, re-epithelialization, and collagen deposition.
  • Employed keratinocyte-specific knockout mouse models (dedicator of cytokinesis 5 - Dock5).
  • Investigated protein interactions including unconventional myosin 1c (Myo1c) and Dock5.

Main Results:

  • Liraglutide significantly accelerated wound closure in diabetic mice.
  • Liraglutide enhanced keratinocyte proliferation, migration, and adhesion.
  • The healing effects were dependent on Dock5, with abrogation in knockout models.
  • Liraglutide stabilizes Myo1c, enhancing the Myo1c/Dock5 interaction.

Conclusions:

  • Liraglutide promotes diabetic wound healing through Myo1c stabilization and enhanced Myo1c/Dock5 interaction.
  • This mechanism involves direct binding of liraglutide to Myo1c at arginine 93.
  • Liraglutide shows potential as an effective therapeutic agent for diabetic wound pathologies.
Keywords:
Dock5diabetic wound healingkeratinocyte functionliraglutide

More Related Videos

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

4.4K
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

2.8K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
308
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
149